Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
<p>Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.</p>
Αποθηκεύτηκε σε:
| Κύριος συγγραφέας: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| Άλλοι συγγραφείς: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| Έκδοση: |
2025
|
| Θέματα: | |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
ανά: Seyed Reza Mousavi (13223324)
Έκδοση: (2025) -
The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
ανά: Seyed Reza Mousavi (13223324)
Έκδοση: (2025) -
Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
ανά: Seyed Reza Mousavi (13223324)
Έκδοση: (2025) -
Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
ανά: Seyed Reza Mousavi (13223324)
Έκδοση: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
ανά: Anna Starshinova (22571846)
Έκδοση: (2025)